These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Increased Expression and Amplification of Li X; Zhang J; Yang C; Li J; Wang J; Huang W; Zeng L; Liang X; Long W; Zhang X Microbiol Spectr; 2022 Aug; 10(4):e0095522. PubMed ID: 35900090 [TBL] [Abstract][Full Text] [Related]
23. Resistance to Ceftazidime/Avibactam in Campogiani L; Vitale P; Lodi A; Imeneo A; Fontana C; D'Agostini C; Compagno M; Coppola L; Spalliera I; Malagnino V; Teti E; Iannetta M; Andreoni M; Sarmati L Antibiotics (Basel); 2023 Apr; 12(5):. PubMed ID: 37237722 [No Abstract] [Full Text] [Related]
24. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Tumbarello M; Raffaelli F; Giannella M; Mantengoli E; Mularoni A; Venditti M; De Rosa FG; Sarmati L; Bassetti M; Brindicci G; Rossi M; Luzzati R; Grossi PA; Corona A; Capone A; Falcone M; Mussini C; Trecarichi EM; Cascio A; Guffanti E; Russo A; De Pascale G; Tascini C; Gentile I; Losito AR; Bussini L; Corti G; Ceccarelli G; Corcione S; Compagno M; Giacobbe DR; Saracino A; Fantoni M; Antinori S; Peghin M; Bonfanti P; Oliva A; De Gasperi A; Tiseo G; Rovelli C; Meschiari M; Shbaklo N; Spanu T; Cauda R; Viale P Clin Infect Dis; 2021 Nov; 73(9):1664-1676. PubMed ID: 33618353 [TBL] [Abstract][Full Text] [Related]
25. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067 [TBL] [Abstract][Full Text] [Related]
26. Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Cui X; Shan B; Zhang X; Qu F; Jia W; Huang B; Yu H; Tang YW; Chen L; Du H Front Microbiol; 2020; 11():1365. PubMed ID: 32655534 [No Abstract] [Full Text] [Related]
27. In Vitro Activities and Inoculum Effects of Ceftazidime-Avibactam and Aztreonam-Avibactam against Carbapenem-Resistant Kim T; Lee SC; Bae M; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Chong YP Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33334045 [TBL] [Abstract][Full Text] [Related]
28. In vitro activity of ceftazidime/avibactam against carbapenem-nonsusceptible Klebsiella penumoniae isolates collected during the first wave of the SARS-CoV-2 pandemic: a Southern Italy, multicenter, surveillance study. La Bella G; Lopizzo T; Lupo L; Angarano R; Curci A; Manti B; La Salandra G; Mosca A; De Nittis R; Arena F J Glob Antimicrob Resist; 2022 Dec; 31():236-238. PubMed ID: 36208851 [TBL] [Abstract][Full Text] [Related]
29. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient. Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787 [TBL] [Abstract][Full Text] [Related]
30. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella Guo Y; Liu N; Lin Z; Ba X; Zhuo C; Li F; Wang J; Li Y; Yao L; Liu B; Xiao S; Jiang Y; Zhuo C Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677 [TBL] [Abstract][Full Text] [Related]
32. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections. Zhen S; Wang H; Feng S Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869 [TBL] [Abstract][Full Text] [Related]
33. Emergence of Hypervirulent Ceftazidime/Avibactam-Resistant Li D; Liao W; Huang HH; Du FL; Wei DD; Mei YF; Long D; Wan LG; Liu Y; Zhang W Infect Drug Resist; 2020; 13():2673-2680. PubMed ID: 32821131 [TBL] [Abstract][Full Text] [Related]
34. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program. Lin LY; Debabov D; Chang W; Stone G; Riccobene T Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651 [No Abstract] [Full Text] [Related]
35. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration. Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Chen Y; Huang HB; Peng JM; Weng L; Du B Microbiol Spectr; 2022 Apr; 10(2):e0260321. PubMed ID: 35377233 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018. Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971 [TBL] [Abstract][Full Text] [Related]
38. Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25. Findlay J; Poirel L; Bouvier M; Gaia V; Nordmann P Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):639-644. PubMed ID: 36877262 [TBL] [Abstract][Full Text] [Related]
39. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa]. Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717 [TBL] [Abstract][Full Text] [Related]
40. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]